JP2003529370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003529370A5 JP2003529370A5 JP2001572983A JP2001572983A JP2003529370A5 JP 2003529370 A5 JP2003529370 A5 JP 2003529370A5 JP 2001572983 A JP2001572983 A JP 2001572983A JP 2001572983 A JP2001572983 A JP 2001572983A JP 2003529370 A5 JP2003529370 A5 JP 2003529370A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antibody fragment
- tumor
- fragment
- angiogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54096700A | 2000-03-31 | 2000-03-31 | |
| US09/540,967 | 2000-03-31 | ||
| PCT/US2001/010505 WO2001075109A2 (en) | 2000-03-31 | 2001-03-30 | Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003529370A JP2003529370A (ja) | 2003-10-07 |
| JP2003529370A5 true JP2003529370A5 (enExample) | 2008-05-15 |
Family
ID=24157649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001572983A Pending JP2003529370A (ja) | 2000-03-31 | 2001-03-30 | 血管浸透性に対する有害な作用を有さないｖｅ−カドヘリンに対する拮抗薬抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US7371574B2 (enExample) |
| EP (1) | EP1268799B1 (enExample) |
| JP (1) | JP2003529370A (enExample) |
| AT (1) | ATE425255T1 (enExample) |
| AU (1) | AU2001249737A1 (enExample) |
| CA (1) | CA2404576A1 (enExample) |
| CY (1) | CY1109097T1 (enExample) |
| DE (1) | DE60137915D1 (enExample) |
| DK (1) | DK1268799T3 (enExample) |
| ES (1) | ES2323938T3 (enExample) |
| PT (1) | PT1268799E (enExample) |
| WO (1) | WO2001075109A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7481999B2 (en) | 1998-05-05 | 2009-01-27 | Adherex Technologies, Inc. | Compounds and methods for modulating OB-cadherin-mediated function |
| CA2506037A1 (en) | 2002-11-14 | 2004-06-10 | Adherex Technologies, Inc. | Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion |
| JP2004175689A (ja) * | 2002-11-25 | 2004-06-24 | Kureha Chem Ind Co Ltd | 癌転移抑制剤 |
| US20040167076A1 (en) * | 2003-02-14 | 2004-08-26 | Stamer W. Daniel | Modulation of aqueous humor outflow by targeting vascular-endothelial-cadherin in schlemm's canal cells |
| GB0602063D0 (en) | 2006-02-02 | 2006-03-15 | Univ Manchester | Cell Culture |
| US9207242B2 (en) * | 2008-10-09 | 2015-12-08 | The University Of Hong Kong | Cadherin-17 as diagnostic marker and therapeutic target for liver cancer |
| WO2011071541A2 (en) * | 2009-12-11 | 2011-06-16 | The Scripps Research Institute | Cadherin modulatory agents |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5036003A (en) * | 1987-08-21 | 1991-07-30 | Monsanto Company | Antibodies to VPF |
| WO1993008210A1 (en) * | 1991-10-18 | 1993-04-29 | Beth Israel Hospital Association | Vascular permeability factor targeted compounds |
| US5660827A (en) * | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
| US5877289A (en) * | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
| EP0627940B1 (en) * | 1992-03-05 | 2003-05-07 | Board of Regents, The University of Texas System | Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors |
| US6004555A (en) * | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
| US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| CA2111573C (en) * | 1992-04-17 | 2002-11-26 | Shintaro Suzuki | Cadherin materials and methods |
| US5597725A (en) * | 1992-04-17 | 1997-01-28 | Doheny Eye Institute | Cadherin-specific antibodies and hybridoma cell lines |
| US5646250A (en) * | 1992-04-17 | 1997-07-08 | Doheny Eye Institute | Cadherin polypeptides |
| US5840301A (en) * | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
| US5861499A (en) * | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
| US5730977A (en) * | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| US20050222037A1 (en) * | 1998-05-05 | 2005-10-06 | Adherex Technologies, Inc. | Compounds and methods for modulating VE-cadherin-mediated function |
| AU759144B2 (en) * | 1998-05-05 | 2003-04-03 | Adherex Technologies Inc. | Compounds and methods for modulating nonclassical cadherin-mediated functions |
| US20030206902A1 (en) * | 2001-03-05 | 2003-11-06 | Fang Liao | Ve-cadherin and vegfr-2 antagonists for therapeutic modulation of angiogenesis |
-
2001
- 2001-03-30 AU AU2001249737A patent/AU2001249737A1/en not_active Abandoned
- 2001-03-30 ES ES01922997T patent/ES2323938T3/es not_active Expired - Lifetime
- 2001-03-30 CA CA002404576A patent/CA2404576A1/en not_active Abandoned
- 2001-03-30 EP EP01922997A patent/EP1268799B1/en not_active Expired - Lifetime
- 2001-03-30 JP JP2001572983A patent/JP2003529370A/ja active Pending
- 2001-03-30 AT AT01922997T patent/ATE425255T1/de active
- 2001-03-30 PT PT01922997T patent/PT1268799E/pt unknown
- 2001-03-30 WO PCT/US2001/010505 patent/WO2001075109A2/en not_active Ceased
- 2001-03-30 DK DK01922997T patent/DK1268799T3/da active
- 2001-03-30 DE DE60137915T patent/DE60137915D1/de not_active Expired - Lifetime
-
2002
- 2002-01-02 US US10/040,128 patent/US7371574B2/en not_active Expired - Fee Related
-
2008
- 2008-03-26 US US12/056,173 patent/US20090060909A1/en not_active Abandoned
- 2008-03-26 US US12/056,116 patent/US20080311121A1/en not_active Abandoned
- 2008-03-26 US US12/056,146 patent/US20080317750A1/en not_active Abandoned
-
2009
- 2009-05-25 CY CY20091100557T patent/CY1109097T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7820448B2 (ja) | 新規のサイトカインプロドラッグ | |
| US11578131B2 (en) | Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules | |
| US20220169751A1 (en) | Multimeric ox40 binding molecules and uses thereof | |
| KR102412023B1 (ko) | 레날리도마이드 또는 포말리도마이드 및 ｃｄ38 항체-감쇠 인터페론-알파 구성체의 조합, 및 이의 용도 | |
| EP3265575B1 (en) | Cd20 binding molecules and uses thereof | |
| JP7358365B2 (ja) | がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用 | |
| AU2017299610B2 (en) | Multimeric CD40 binding molecules and uses thereof | |
| BR112020026862A2 (pt) | antagonistas antitumorais de reguladores de pontos de verificação imunológica | |
| KR102247704B1 (ko) | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 | |
| KR102909908B1 (ko) | 항pd-1/항her2 천연항체 구조 헤테로다이머계의 이중특이성 항체 및 그 제조방법 | |
| JP2011504176A (ja) | マクロファージ刺激タンパク質受容体（ｒｏｎ）の阻害およびその処置の方法 | |
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| WO2013023557A1 (zh) | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 | |
| JP2018186822A (ja) | 血管内皮成長因子融合タンパク質 | |
| CN118459588A (zh) | 抗c-met抗体 | |
| JP2021531821A (ja) | 効率的に発現されるｅｇｆｒ及びｐｄ−ｌ１二重特異性結合タンパク質 | |
| JP2003529370A5 (enExample) | ||
| CN113544152B (zh) | Flt3激动剂抗体及其用途 | |
| CN119285765A (zh) | 抗金属硫蛋白抗体及其用途 | |
| KR20180010178A (ko) | Jag1에 결합하는 항체 치료제 | |
| CN121646609A (zh) | Tnf超家族成员免疫细胞因子及其用途 | |
| WO2023222035A1 (zh) | 抗tigit抗体与il2的融合蛋白或其变体及其应用 | |
| JP2003529370A (ja) | 血管浸透性に対する有害な作用を有さないｖｅ−カドヘリンに対する拮抗薬抗体 | |
| CN119613548A (zh) | APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用 | |
| CN120344264A (zh) | 突变体il-2多肽和il-2前药 |